Trial tests new hope for controlling rare, relapsing autoimmune disease
NCT ID NCT03164473
Summary
This study tested whether the drug rituximab is better than the standard drug azathioprine at keeping a rare autoimmune disease called EGPA in remission. It involved 98 adults whose disease had recently been brought under control. The goal was to see which drug helped patients stay in remission longer while reducing their need for steroid medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin
Paris, Paris, 75014, France
Conditions
Explore the condition pages connected to this study.